基因編輯細胞療法治療第一型糖尿病取得突破
Breakthrough in Gene-Edited Cell Therapy for Type 1 Diabetes
第一型糖尿病（T1D）是一種具有挑戰性的自體免疫疾病，身體會攻擊自身產生胰島素的胰臟細胞。
Type 1 Diabetes (T1D) is a challenging autoimmune condition where the body attacks its own insulin-producing pancreatic cells.
多年來，患者一直依賴胰島素注射來控制症狀，而非解決根本原因。
For years, patients have relied on insulin injections to manage symptoms rather than address the root cause.
透過利用CRISPR/Cas9技術，研究人員可以將幹細胞轉化為新的β細胞，並進行編輯使其產生「免疫逃避」功能。
By utilizing CRISPR/Cas9 technology, researchers can transform stem cells into new beta cells and edit them to become "immune-evasive."
這項創新解決了兩個關鍵問題：它提供了無限的細胞供應，並消除了對危險且需終身服用之免疫抑制劑的需求。
This innovation solves two critical issues: it provides an unlimited supply of cells and removes the need for dangerous, lifelong immunosuppressant medication.
像Vertex Pharmaceuticals和CRISPR Therapeutics等領先公司，已經在進行臨床人體試驗，並取得了令人期待的初步成果。
Leading firms like Vertex Pharmaceuticals and CRISPR Therapeutics are already conducting human clinical trials with promising early results.
科學家們致力於證實其長期安全性，並建立有效的方法來擴大這種治療的規模，以便最終能惠及全球數百萬患者，標誌著再生醫學進入了新時代。
Scientists are focused on proving long-term safety and establishing efficient ways to scale this treatment so it can eventually reach millions of patients worldwide, marking a new era in regenerative medicine.
